Did Quest Diagnostics meet expectations in Q1 2025?

The release does not include consensus estimates, so it cannot be judged against expectations from this filing alone. On its face, the quarter showed double-digit revenue growth, 12.8% growth in reported diluted EPS, and 8.3% growth in adjusted diluted EPS. Management attributed the quarter's weather-related softness to a March rebound. Comparing the results against analyst consensus is necessary to assess the beat or miss.

Why did reported EPS guidance rise while adjusted EPS guidance stayed the same?

The increase in reported EPS guidance to $8.62 to $8.87 from $8.34 to $8.59 is driven by special items included in GAAP results but excluded from adjusted figures. The main items are a pre-tax $46 million gain from a CARES Act payroll tax credit and an $8 million non-recurring lease gain. These one-time gains boost GAAP earnings without changing the underlying operating outlook, which management kept at $9.55 to $9.80 on an adjusted basis.

Is the company's organic growth healthy?

Organic growth appears modest. Management cited roughly 2.5% organic revenue growth, and organic requisition volume declined 0.9%. Most of the 12.1% headline revenue increase came from acquisitions and large enterprise account contributions. Investors should monitor whether organic volume turns positive as weather disruptions fade and as the company integrates recent acquisitions.

Why did interest expense rise so sharply, and what does it mean for investors?

Interest expense, net rose to $67 million from $43 million, reflecting higher debt levels tied to recent acquisitions and borrowing activity. Total long-term debt increased to $5.86 billion from $5.62 billion at year-end 2024. Higher interest costs reduce net income and free cash flow, and they increase sensitivity to interest rate changes and leverage. Investors should track whether deleveraging progresses over the coming quarters.

Is the company's cash position a concern?

Cash and equivalents declined to $188 million from $549 million at December 31, 2024, mainly due to debt repayment of $600 million, dividends of $84 million, and share repurchase-related and tax withholding outflows. Operating cash flow of $314 million partly offset these uses. The balance is lower than the prior year-end, but the company also has undrawn capacity under its credit facilities, which the release does not detail. Management's full-year outlook for approximately $1.45 billion in operating cash flow and about $500 million in capital expenditures suggests ample internal funding for planned uses.

DGX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 22, 2025. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) reported first quarter 2025 results on April 22, 2025, with net revenues of $2.65 billion^a, up 12.1% year over year.

Management cited roughly 2.5% organic growth, with the remainder driven by acquisitions and large enterprise accounts, demand for its advanced diagnostics portfolio, and expanded health plan access. Reported diluted EPS was $1.94^b (up 12.8%), and adjusted diluted EPS was $2.21 (up 8.3%). Adjusted operating margin expanded to 15.3% from 14.8%, while reported operating margin rose to 13.0% from 12.7%.

Organic requisition volume declined 0.9%, which is a point investors will want to watch, since headline growth relied heavily on acquired volume and pricing contributions. Cash flow was a bright spot, with operating cash flow of $314 million^c, up 103% from $154 million a year earlier, though that comparison benefited from a weak prior-year quarter. Interest expense more than doubled to $67 million from $43 million, reflecting higher debt levels following borrowings to refinance maturing notes.

Cash and equivalents fell sharply to $188 million^d from $549 million at year-end 2024, and total debt rose modestly as the company repaid $600 million of debt and borrowed $215 million. Management reaffirmed full-year 2025 revenue guidance of $10.70 to $10.85 billion (8.4% to 9.9% growth) and adjusted diluted EPS guidance of $9.55 to $9.80.

Reported diluted EPS guidance was raised to $8.62 to $8.87 from $8.34 to $8.59, largely reflecting a $46 million one-time payroll tax credit gain under the CARES Act and an $8 million non-recurring lease gain. Operating cash flow guidance was lowered to approximately $1.45 billion from $1.5 billion, although the press release table is ambiguous on this point and the direction should be confirmed against the full release.

02—Key points

Key Highlights

Q1 2025 net revenues of $2.65 billion, up 12.1% YoY, including approximately 2.5% organic growth per management
Organic requisition volume declined 0.9%, while total requisition volume grew 12.4%, indicating growth driven by acquisitions
Reported diluted EPS of $1.94 (up 12.8%); adjusted diluted EPS of $2.21 (up 8.3%)
Adjusted operating margin of 15.3%, up from 14.8%; reported operating margin of 13.0%, up from 12.7%
Interest expense, net more than doubled to $67 million from $43 million, a notable drag on net income
Operating cash flow of $314 million, up 103% YoY, but cash on hand fell to $188 million from $549 million at year-end 2024
Full-year 2025 adjusted EPS guidance of $9.55 to $9.80 and revenue guidance of $10.70 to $10.85 billion reaffirmed; reported EPS guidance raised to $8.62 to $8.87 on one-time gains

03—Questions

Frequently Asked Questions

Did Quest Diagnostics meet expectations in Q1 2025?
The release does not include consensus estimates, so it cannot be judged against expectations from this filing alone. On its face, the quarter showed double-digit revenue growth, 12.8% growth in reported diluted EPS, and 8.3% growth in adjusted diluted EPS. Management attributed the quarter's weather-related softness to a March rebound. Comparing the results against analyst consensus is necessary to assess the beat or miss.
Why did reported EPS guidance rise while adjusted EPS guidance stayed the same?
The increase in reported EPS guidance to $8.62 to $8.87 from $8.34 to $8.59 is driven by special items included in GAAP results but excluded from adjusted figures. The main items are a pre-tax $46 million gain from a CARES Act payroll tax credit and an $8 million non-recurring lease gain. These one-time gains boost GAAP earnings without changing the underlying operating outlook, which management kept at $9.55 to $9.80 on an adjusted basis.
Is the company's organic growth healthy?
Organic growth appears modest. Management cited roughly 2.5% organic revenue growth, and organic requisition volume declined 0.9%. Most of the 12.1% headline revenue increase came from acquisitions and large enterprise account contributions. Investors should monitor whether organic volume turns positive as weather disruptions fade and as the company integrates recent acquisitions.
Why did interest expense rise so sharply, and what does it mean for investors?
Interest expense, net rose to $67 million from $43 million, reflecting higher debt levels tied to recent acquisitions and borrowing activity. Total long-term debt increased to $5.86 billion from $5.62 billion at year-end 2024. Higher interest costs reduce net income and free cash flow, and they increase sensitivity to interest rate changes and leverage. Investors should track whether deleveraging progresses over the coming quarters.
Is the company's cash position a concern?
Cash and equivalents declined to $188 million from $549 million at December 31, 2024, mainly due to debt repayment of $600 million, dividends of $84 million, and share repurchase-related and tax withholding outflows. Operating cash flow of $314 million partly offset these uses. The balance is lower than the prior year-end, but the company also has undrawn capacity under its credit facilities, which the release does not detail. Management's full-year outlook for approximately $1.45 billion in operating cash flow and about $500 million in capital expenditures suggests ample internal funding for planned uses.

04—Continue

← View all 8-K filings